Literature DB >> 9256892

Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles.

C Ciesielski-Carlucci1, P Leong, C Jacobs.   

Abstract

Anaphylaxis is one of the most catastrophic, although infrequent, potential side effects of chemotherapy. We report the case of a patient who developed respiratory distress and who could not be resuscitated after his sixth cycle of cisplatin and paclitaxel for squamous carcinoma of the lung and false vocal cord. Autopsy confirmed anaphylaxis as the cause of death. The major hypersensitivity profiles of these two agents, as described in case reports and in the medical literature, were reviewed to determine which of the two therapies was the underlying cause of the patient's reaction. Anaphylaxis has been reported with both cisplatin and paclitaxel. Cisplatin is argued to be the most likely etiology for anaphylaxis in this case.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256892     DOI: 10.1097/00000421-199708000-00010

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  3 in total

1.  Postmortem findings after fatal anaphylactic reactions.

Authors:  R S Pumphrey; I S Roberts
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

2.  Protracted anaphylaxis developed after peginterferon α-2a administration for chronic hepatitis C.

Authors:  Akihiko Sakatani; Yoshinori Doi; Takaaki Matsuda; Yasutaka Sasai; Naohiro Nishida; Megumi Sakamoto; Naoto Uenoyama; Yoshiya Matsumoto; Kazuo Kinoshita
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

3.  Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.

Authors:  H Gelderblom; A Sparreboom; M J de Jonge; W J Loos; E Wilms; M A Mantel; B Hennis; I Camlett; J Verweij; M E van der Burg
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.